Literature DB >> 8159389

Transcatheter embolotherapy for the treatment of pelvic congestion syndrome.

M J Sichlau1, J S Yao, R L Vogelzang.   

Abstract

BACKGROUND: Both medical and surgical treatments have been used for pelvic congestion syndrome. An analogous condition in males, varicocele testis, has been treated successfully for many years by transcatheter embolotherapy. CASES: We performed percutaneous transcatheter embolization of the ovarian veins in three women with chronic pelvic pain and venographically demonstrated pelvic venous congestion. In all three cases, the ovarian veins were embolized bilaterally from the femoral approach, using stainless-steel coils. After the treatment, all subjects experienced a dramatic decrease in pelvic pain, as well as an improvement in two or more preexisting symptoms, including extremity swelling, dyspareunia, external varicosities, constipation, and emotional disturbance. One patient's symptoms recurred at 1.2 years and required surgery; the other two continue to have long-term benefit.
CONCLUSION: These findings suggest that pelvic venous congestion was the likely etiologic factor in pelvic pain experienced by these women and that transcatheter ovarian vein embolotherapy may be an effective treatment for such a condition.

Entities:  

Mesh:

Year:  1994        PMID: 8159389

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

1.  Quantitative evaluation of the utero-ovarian venous pattern in the adult human female cadaver with plastination.

Authors:  Mircea L Pavkov; Jürgen Koebke; Hans-P Notermans; Jost Brökelmann
Journal:  World J Surg       Date:  2004-01-20       Impact factor: 3.352

Review 2.  Pelvic pain: a chronic visceral pain syndrome.

Authors:  U Wesselmann; P P Czakanski
Journal:  Curr Pain Headache Rep       Date:  2001-02

Review 3.  Female Pelvic Vein Embolization: Indications, Techniques, and Outcomes.

Authors:  Anthony James Lopez
Journal:  Cardiovasc Intervent Radiol       Date:  2015-03-25       Impact factor: 2.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.